Vinorelbine, Pertuzumab, and Trastuzumab for Breast Cancer Vinorelbine, Pertuzumab, and Trastuzumab for Breast Cancer

Is the combination of vinorelbine with dual HER2-targeted therapy a good first-line option for patients needing an alternative to docetaxel?Breast Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Related Links:

Authors: Kong Y, Dong Q, Ji H, Sang M, Ding Y, Zhao M, Yang H, Geng C Abstract BACKGROUND The purpose of the present study was to evaluate the effect of leptin and leptin receptor (LEPR) expression on the efficacy of neoadjuvant chemotherapy in breast cancer. MATERIAL AND METHODS There were 325 breast cancer patients with complete data enrolled in this study. Patients were categorized into 3 groups: pathological complete response group, non-pathological complete response group, and progressive disease group. Immunohistochemistry was performed to determine leptin and its receptor LEPR expression levels that were com...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Condition:   Advanced Breast Cancer Interventions:   Drug: SHR6390;   Drug: Placebo;   Drug: Fulvestrant Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
The authors would like to note the replacement of Fig.  2b, for which Fig. 2a was placed erringly, with appropriate Fig. 2b.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Conclusion Several TISC-based immunotherapeutic approaches are under development in various stages of preclinical studies. As outlined in this review article, a careful and more exhaustive genetic and metabolic understanding of TISC-associated phenotypes is critical to develop novel TISC based immunotherapies. Various components within the tumor microenvironment such as tumor cells, infiltrating immune cells, and supporting stromal cells impact the TISC metabolism. This unique metabolic profile leads to upregulation of certain enzymes and proteins such as ALDH1, CEP55, IDO COA1 etc., which can be utilized for development ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Breast Cancer Interventions:   Drug: Docetaxel;   Drug: Cyclophosphamide Sponsor:   Fudan University Recruiting
Source: - Category: Research Source Type: clinical trials
Conclusion: In EBC, PTEN-loss is an independent predictor of poor outcome. When occurring singly, PTEN-loss and PIK3CA mutations have opposite prognostic impact. In HER2-positive disease, assessment of PTEN-loss by IHC appears unreliable and the marker is without clear prognostic significance.
Source: Cancer Genomics and Proteomics - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
In conclusion, our WGCNA analysis identified candidate prognostic biomarkers for further basic and clinical researches. Introduction Breast cancer is a frequently diagnosed malignancy and the leading cause of cancer death among females around the world, accounting for 24% of cancer diagnoses and 15% of cancer deaths in females. According to Global Cancer Statistics 2018, there will be nearly 2.1 million new cases diagnosed globally, with ~62 thousand deaths. The incident rates of breast cancer increased in most developing countries during last decades, resulting from a combination of social and economic factors, incl...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, we confirm our initial findings from the proteomic screen and demonstrate that LASP1 can interact with both eIF4A and eIF4B. Importantly, the LASP1-eIF4A and LASP1-eIF4B interaction is shown to be CXCL12-dependent. In addition, the ability of CXCR4 to impact the phosphorylation of eIF4F regulatory proteins is provided. Taken together, we hypothesize that activation of CXCR4 can promote eIF4F complex formation and activity through LASP1 and cell signaling. As a result, the translation of oncogenic proteins is promoted thereby mediating an invasive and metastatic phenotype commonly associated with CXCR4. Mate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsCirculating formate is reduced in HER2+ breast cancer, non-small cell lung cancer and highly obese patients relative to healthy controls. Further studies are required to determine the relevance of these observations in other cancer types and diseases.
Source: Cancer and Metabolism - Category: Cancer & Oncology Source Type: research
Conclusion and Perspective With in-depth understandings of antibodies, linkers, and payloads, ADCs have also achieved great development. The linkage strategy and target diversity have already improved the delivery of the payloads to tumor tissues and reduced exposure to normal tissues. With the development of payloads, some novel potent payloads are used by ADCs, which allows researchers to exploit novel linkers to attach the antibody and payloads without disturbing their potency (Dragovich et al., 2018). Furthermore, some irrelevant antigen-target ADCs also may exert toxicity to tumor cells due to the vascular gap of tum...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | Health | Hematology | HER2 | Herceptin | Taxotere